GameStop Corp. vs Eli Lilly And Co — how do they compare? GameStop Corp. trades at $22.27 (market cap $9.99B), while Eli Lilly And Co trades at $1,170.65 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 103.1× GameStop Corp.'s market cap, and Eli Lilly And Co pays a 0.6% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | LLY | |
|---|---|---|
Market Cap | $9.99B | $1.03T |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $1.24K |
52-Week Low | $19.94 | $625.65 |
Enterprise Value | $5.96B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.36, down 0.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue declined to $3.82 billion in 2025, but net income improved to $131.3 million, reflecting a profit margin of 3.43%. Recent developments include a partnership with Uber Eats and ongoing efforts to acquire eBay, as announced in Business Wire on June 26, 2026.
The outlook is mixed, with positive EBITDA guidance above $600 million for fiscal 2026 offering upside potential, but risks include revenue declines and dependence on physical media amid Sony's shift away from discs. Analyst sentiment is cautious, with only 16.67% buy ratings, suggesting limited near-term conviction despite operational improvements.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →